论文部分内容阅读
目的比较非布司他和别嘌醇降尿酸治疗高尿酸血症的临床疗效。方法选取祁阳县中医医院2015年5月—2016年6月收治的高尿酸血症患者98例,根据随机抽签原则分为对照组和观察组,各49例。对照组患者给予别嘌醇片治疗,观察组患者给予非布司他片治疗,两组患者均持续治疗1个月。比较两组患者治疗前后血尿酸水平及尿酸达标率和不良反应发生情况。结果治疗前,两组患者血尿酸水平比较,差异无统计学意义(P>0.05);治疗后,观察组患者血尿酸水平低于对照组(P<0.01)。观察组患者血尿酸达标率高于对照组,不良反应发生率低于对照组(P<0.05)。结论非布司他治疗高尿酸血症的临床疗效优于别嘌醇,其具有更强的降尿酸作用,且用药安全性高。
Objective To compare the clinical efficacy of febuxostat and allopurinol-lowering uric acid in the treatment of hyperuricemia. Methods 98 cases of hyperuricemia patients were treated in Qiyang Hospital of Traditional Chinese Medicine from May 2015 to June 2016. The patients were divided into control group and observation group according to random sampling principle, each of 49 cases. Patients in the control group were treated with allopurinol tablets, and patients in the observation group were treated with febuxostat. Patients in both groups were treated for one month. The levels of uric acid and uric acid in the two groups before and after treatment were compared, and the occurrence of adverse reactions were compared. Results Before treatment, there was no significant difference in serum uric acid between the two groups (P> 0.05). After treatment, serum uric acid level in the observation group was lower than that in the control group (P <0.01). The observed rate of blood uric acid in observation group was higher than that of control group, and the incidence of adverse reactions was lower than that of control group (P <0.05). Conclusion The clinical efficacy of febuxostat in the treatment of hyperuricemia is better than that of allopurinol, which has a better effect of lowering uric acid and safe administration.